These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
81 related articles for article (PubMed ID: 6147492)
1. Prolonging prostacyclin production by nafazatrom or dipyridamole. Deckmyn H; Gresele P; Arnout J; Todisco A; Vermylen J Lancet; 1984 Aug; 2(8399):410-1. PubMed ID: 6147492 [No Abstract] [Full Text] [Related]
2. Drug effects on output of prostacyclin from isolated lungs. Bakhle YS; Pankhania JJ Biochem Pharmacol; 1987 Oct; 36(20):3540-3. PubMed ID: 3118880 [No Abstract] [Full Text] [Related]
3. Mechanism of the stimulation of prostaglandin H synthase and prostacyclin synthase by the antithrombotic and antimetastatic agent, nafazatrom. Marnett LJ; Siedlik PH; Ochs RC; Pagels WR; Das M; Honn KV; Warnock RH; Tainer BE; Eling TE Mol Pharmacol; 1984 Sep; 26(2):328-35. PubMed ID: 6434940 [TBL] [Abstract][Full Text] [Related]
4. Investigations on the role of arachidonic acid metabolism pathways in the antithrombotic activity of nafazatrom and molsidomine. Massad L; Plotkine M; Boulu RG Thromb Res; 1988 Jun; 50(5):617-25. PubMed ID: 3137682 [TBL] [Abstract][Full Text] [Related]
5. Enhanced prostacyclin production by dipyridamole in man. Neri Serneri GG; Masotti G; Poggesi L; Galanti G; Morettini A Eur J Clin Pharmacol; 1981; 21(1):9-15. PubMed ID: 7037426 [TBL] [Abstract][Full Text] [Related]
6. Nafazatrom (BAY g 6575), a potent stimulator of prostacyclin release from cardiac and renal vessel wall. Klitzke AK Arch Int Pharmacodyn Ther; 1984 Oct; 271(2):220-8. PubMed ID: 6391401 [TBL] [Abstract][Full Text] [Related]
7. [Dose-dependent increase in prostacyclin synthesis from various vascular tissues by dipyridamole]. Sinzinger H; Silberbauer K Wien Klin Wochenschr; 1982 Dec; 94(23):630-2. PubMed ID: 6762767 [TBL] [Abstract][Full Text] [Related]
8. Dipyridamole: a potent stimulator of prostacyclin (PGI2) biosynthesis. Blass KE; Block HU; Förster W; Pönicke K Br J Pharmacol; 1980 Jan; 68(1):71-3. PubMed ID: 6766769 [TBL] [Abstract][Full Text] [Related]
9. Antiaggregatory efficacy and its time-course after application of acetylsalicylic acid, prostacyclin and nafazatrom in vivo. Herrmann KS Arch Int Pharmacodyn Ther; 1984 Nov; 272(1):150-8. PubMed ID: 6393886 [TBL] [Abstract][Full Text] [Related]
11. Effect of dipyridamole on the formation of 6-oxo-prostaglandin F1 alpha by the rat isolated aorta and ram seminal vesicle microsomes. Bult H; Herman AG; Van de Velde VJ Br J Pharmacol; 1982 Jul; 76(3):453-8. PubMed ID: 7049287 [TBL] [Abstract][Full Text] [Related]
12. Dipyridamole stimulates prostacyclin production in isolated rat aortic tissue. Van de Velde VJ; Bult H; Weisenberger H; Herman AG Arch Int Pharmacodyn Ther; 1982 Apr; 256(2):327-8. PubMed ID: 7049101 [No Abstract] [Full Text] [Related]
13. Mechanism of action of nafazatrom. Seuter F; Busse WD Thromb Res Suppl; 1983; 4():75-80. PubMed ID: 6415860 [No Abstract] [Full Text] [Related]
14. Stimulation of prostacyclin release from vessel wall by Bay g 6575, an antithrombotic compound. Vermylen J; Chamone DA; Verstraete M Lancet; 1979 Mar; 1(8115):518-20. PubMed ID: 85106 [TBL] [Abstract][Full Text] [Related]
15. The effect of prostaglandin modulators on prostate tumor growth and metastasis. Drago JR; Al-Mondhiry HA Anticancer Res; 1984; 4(6):391-4. PubMed ID: 6393859 [TBL] [Abstract][Full Text] [Related]
16. Decreased vascular prostacyclin (PGI2) in diabetic rats. Stimulation of PGI2 release in normal and diabetic rats by the antithrombotic compound Bay g 6575. Carreras LO; Chamone DA; Klerckx P; Vermylen J Thromb Res; 1980 Aug 15-Sep 1; 19(4-5):663-70. PubMed ID: 7003804 [No Abstract] [Full Text] [Related]
17. Inactivation of prostaglandin H synthase and prostacyclin synthase by phenylbutazone. Requirement for peroxidative metabolism. Reed GA; Griffin IO; Eling TE Mol Pharmacol; 1985 Jan; 27(1):109-14. PubMed ID: 3917545 [TBL] [Abstract][Full Text] [Related]
18. A clinical study of nafazatrom in advanced human breast cancer. Jones AL; Powles TJ; Forgeson GV; Coombes RC Cancer Chemother Pharmacol; 1991; 27(4):326-8. PubMed ID: 1998990 [TBL] [Abstract][Full Text] [Related]
19. The relationship between dose, pharmacokinetics, plasma-concentrations and antithrombotic effects of nafazatrom. Philipp E; Ritter W; Patzschke K Thromb Res Suppl; 1983; 4():129-33. PubMed ID: 6579706 [TBL] [Abstract][Full Text] [Related]